

# The use of cardiac biopsy to demonstrate reduced cardiotoxicity in patients treated with pegylated liposomal doxorubicin

Annals of Oncology

9, 711-716

DOI: [10.1023/a:1008216430806](https://doi.org/10.1023/a:1008216430806)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Significant Increase in Antitumor Potency of Doxorubicin Hc1 by its Encapsulation in Pegylated Liposomes. <i>Journal of Liposome Research</i> , 1999, 9, 523-538.	1.5	33
2	Pegylated liposomal adriamycin: a review of current and future applications. <i>Pharmaceutical Science &amp; Technology Today</i> , 1999, 2, 473-477.	0.7	11
3	A Risk and Benefit Assessment of Treatment for AIDS-Related Kaposi's Sarcoma. <i>Drug Safety</i> , 1999, 20, 403-425.	1.4	26
4	Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m <sup>2</sup> . <i>Annals of Oncology</i> , 2000, 11, 1029-1034.	0.6	530
5	Strategies offering protection from the toxic effects of anticancer treatments with a focus on chemoprotective agents. <i>Current Opinion in Oncology</i> , 2000, 12, 289-296.	1.1	3
6	Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. <i>Anti-Cancer Drugs</i> , 2000, 11, 123-127.	0.7	82
7	Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. <i>Anti-Cancer Drugs</i> , 2000, 11, 555-563.	0.7	78
8	Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. <i>Cancer</i> , 2000, 89, 1037-1047.	2.0	369
9	Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. <i>Investigational New Drugs</i> , 2000, 18, 253-259.	1.2	43
10	Liposomes as Vehicles for Targeted Therapy of Cancer. Part 2: Clinical Development. <i>Clinical Oncology</i> , 2000, 12, 16-24.	0.6	28
11	Second-Line Treatment of Ovarian Cancer. <i>Oncologist</i> , 2000, 5, 26-35.	1.9	277
12	Novel approaches to the treatment of primary amyloidosis. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 2343-2350.	1.9	13
13	Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. <i>European Journal of Cancer</i> , 2001, 37, 878-883.	1.3	49
14	Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy. <i>Cancer Investigation</i> , 2001, 19, 424-436.	0.6	506
15	Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. <i>European Journal of Cancer</i> , 2001, 37, 2015-2022.	1.3	58
16	Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2001, 12, 1743-1747.	0.6	20
17	Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3117-3125.	0.8	75
18	Caelyx: treatment for relapsing ovarian cancer. <i>British Journal of Hospital Medicine</i> , 2001, 62, 611-616.	0.3	3

#	ARTICLE	IF	CITATIONS
19	Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome. <i>Biomedical Applications</i> , 2001, 757, 257-267.	1.7	34
20	Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 115-120.	2.0	40
21	Liposomal Medicinal Forms of Antitumor Drugs (A Review). <i>Pharmaceutical Chemistry Journal</i> , 2001, 35, 209-215.	0.3	3
22	Drugs and Cardiotoxicity in HIV and AIDS. <i>Annals of the New York Academy of Sciences</i> , 2001, 946, 179-199.	1.8	57
23	Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials. <i>Seminars in Oncology</i> , 2001, 28, 20-27.	0.8	72
24	Liposomal anthracyclines for breast cancer. <i>Seminars in Oncology</i> , 2001, 28, 32-40.	0.8	15
25	Liposomal doxorubicin (Myocet <sup>®</sup> ) and conventional anthracyclines: a comparison. <i>Breast</i> , 2001, 10, 28-33.	0.9	38
26	Liposomal cancer chemotherapy: current clinical applications and future prospects. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1045-1061.	1.9	27
27	EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx <sup>®</sup> , Doxil <sup>®</sup> ) at a 6-week interval in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2002, 13, 910-918.	0.6	93
28	Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 2360-2364.	0.8	158
29	Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma. <i>Oncology</i> , 2002, 63, 23-30.	0.9	29
30	Pegylated Liposomal Doxorubicin (Doxil <sup>®</sup> ) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience. <i>Cancer Investigation</i> , 2002, 20, 22-29.	0.6	100
31	Predicting Cancer Therapy???Induced Cardiotoxicity. <i>Drug Safety</i> , 2002, 25, 301-311.	1.4	65
32	Minimising the Long-Term Adverse Effects of Childhood Leukaemia Therapy. <i>Drug Safety</i> , 2002, 25, 1057-1077.	1.4	21
33	Polyethylene Glycol-Liposomal Doxorubicin. <i>Drugs</i> , 2002, 62, 2089-2126.	4.9	84
34	Liposome-based drug delivery in breast cancer treatment. <i>Breast Cancer Research</i> , 2002, 4, 95-9.	2.2	392
35	Recent Advances in the Treatment of AIDS-Related Kaposi??s Sarcoma. <i>American Journal of Clinical Dermatology</i> , 2002, 3, 451-462.	3.3	47
36	Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2002, 38, 1992-1997.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Doxorubicin-Induced Mitochondrial Cardiomyopathy. , 2002, , 467-488.		1
38	A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. <i>Cancer</i> , 2002, 95, 2160-2168.	2.0	81
39	Pegylated Liposomal Doxorubicin in Combination Chemotherapy in the Treatment of Previously Untreated Aggressive Diffuse Large-B-Cell Lymphoma. <i>Medical Oncology</i> , 2002, 19, 55-58.	1.2	20
40	Unexpected Low Efficacy of Stealth Liposomal Doxorubicin (Caelyx) and Vinorelbine in Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 77, 185-188.	1.1	14
41	Cardiac Safety of Liposomal Anthracyclines. <i>Oncologist</i> , 2003, 8, 17-24.	1.9	145
42	Congestive heart failure in patients treated with doxorubicin. <i>Cancer</i> , 2003, 97, 2869-2879.	2.0	1,874
43	Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. <i>Colloids and Surfaces B: Biointerfaces</i> , 2003, 30, 129-138.	2.5	297
44	Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 4, 318-328.	1.1	101
45	Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3249-3254.	0.8	83
46	Rate of biodistribution of STEALTH® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003, 1609, 102-108.	1.4	153
47	Spotlight on Polyethylene Glycol-Liposomal Doxorubicin in Solid and Hematological Malignancies and AIDS-Related Kaposi's Sarcoma*. <i>American Journal of Cancer</i> , 2003, 2, 67-72.	0.4	1
48	Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer. <i>Oncologist</i> , 2003, 8, 25-30.	1.9	20
49	Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide. <i>Oncologist</i> , 2003, 8, 39-45.	1.9	30
50	Current Therapies in Ovarian Cancer. <i>Cancer Investigation</i> , 2003, 21, 148-156.	0.6	23
51	Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 1058-1067.	1.3	120
52	Response of Progressive Fibromatosis to Therapy with Liposomal Doxorubicin. <i>Oncology Research and Treatment</i> , 2004, 27, 552-556.	0.8	25
53	Reversible Ageusia after Chemotherapy with Pegylated Liposomal Doxorubicin. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1212-1214.	0.9	10
54	Novel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 501-513.	1.9	5

#	ARTICLE	IF	CITATIONS
55	Advantages of liposomal delivery systems for anthracyclines. <i>Seminars in Oncology</i> , 2004, 31, 5-15.	0.8	204
56	Cardiac safety of liposomal anthracyclines. <i>Seminars in Oncology</i> , 2004, 31, 161-181.	0.8	154
57	Cardiac safety profile of prolonged (â‰¥6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2004, 94, 147-151.	0.6	41
58	Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 53, 329-336.	1.1	151
59	Cardiac profiles of liposomal anthracyclines. <i>Cancer</i> , 2004, 100, 2052-2063.	2.0	117
60	In vivo determination of doxorubicin and its metabolites within the skin using laser scanning microscopy. <i>Laser Physics Letters</i> , 2004, 1, 100-103.	0.6	21
61	Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies. <i>Cancer Investigation</i> , 2004, 22, 663-669.	0.6	109
62	Locoregional effects of pegylated liposomal doxorubicin (Caelyx®) in irradiated area: a phase Iâ€“II study in patients with recurrent squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2004, 40, 1517-1521.	1.3	10
63	Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2004, 1663, 167-177.	1.4	250
64	Cardiotoxicity after liposomal anthracyclines. <i>Lancet Oncology, The</i> , 2004, 5, 654.	5.1	18
65	New treatment strategies for multiple myeloma. <i>Seminars in Hematology</i> , 2004, 41, 2-8.	1.8	11
67	Treatments of AIDS-related Kaposi's sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 253-265.	2.0	48
68	Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. <i>Investigational New Drugs</i> , 2005, 23, 57-62.	1.2	10
69	Approach to the treatment of cutaneous malignancy in HIV-infected patients. <i>Dermatologic Therapy</i> , 2005, 18, 77-86.	0.8	26
70	Pegylated Liposomal Doxorubicin and Cyclophosphamide as First-Line Therapy for Patients with Metastatic or Recurrent Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 150-157.	1.1	33
71	Role of pegylated liposomal doxorubicin in ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 96, 10-18.	0.6	99
72	Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m <sup>2</sup> ) in the treatment of gynecologic cancers. <i>Gynecologic Oncology</i> , 2005, 97, 374-378.	0.6	48
73	Phase II trial of liposomal doxorubicin at 40 mg/m <sup>2</sup> every 4 weeks in endometrial carcinoma: A Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2005, 98, 294-298.	0.6	35

#	ARTICLE	IF	CITATIONS
74	Pathology of radiation and anthracycline cardiotoxicity. <i>Pediatric Blood and Cancer</i> , 2005, 44, 630-637.	0.8	88
75	Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?. <i>Annals of Oncology</i> , 2005, 16, 1210-1211.	0.6	100
76	Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS). <i>Sarcoma</i> , 2005, 9, 127-132.	0.7	27
77	Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates. <i>Clinical Cancer Research</i> , 2005, 11, 3567-3573.	3.2	145
78	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. <i>British Journal of Cancer</i> , 2005, 92, 628-630.	2.9	22
79	Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents. <i>Clinical Cancer Research</i> , 2005, 11, 8230-8234.	3.2	212
80	The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 795-802.	0.6	100
81	Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 6944-6949.	3.2	399
82	Anthracycline cardiotoxicity. <i>Expert Opinion on Drug Safety</i> , 2006, 5, 791-809.	1.0	108
83	CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 2174-2180.	0.6	53
84	Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: A phase II study. <i>Leukemia and Lymphoma</i> , 2006, 47, 1327-1332.	0.6	8
85	Delivery of Liposomal Doxorubicin (Doxil) in a Breast Cancer Tumor Model: Investigation of Potential Enhancement by Pulsed-High Intensity Focused Ultrasound Exposure. <i>Academic Radiology</i> , 2006, 13, 469-479.	1.3	144
86	Cardiac Evaluation, Toxicity and Monitoring in the Treatment of Breast Cancer. <i>Seminars in Breast Disease</i> , 2006, 9, 160-167.	0.0	1
87	Cutaneous malignancy and human immunodeficiency virus disease. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 189-206.	0.6	142
88	Applications of Liposomal Drug Delivery Systems to Cancer Therapy. , 2006, , 595-611.		3
89	Nanoscale Drug Delivery Vehicles for Solid Tumors. , 2006, , 677-719.		1
90	Monitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging. <i>Journal of Nuclear Cardiology</i> , 2006, 13, 415-426.	1.4	54
91	Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 615-623.	1.1	20

#	ARTICLE	IF	CITATIONS
92	Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 102, 338-342.	0.6	5
93	Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2006, 106, 848-858.	2.0	123
94	Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 975-987.	0.9	13
95	Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. <i>Annals of Oncology</i> , 2006, 17, 957-961.	0.6	24
96	Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. <i>Annals of Oncology</i> , 2007, 18, 263-268.	0.6	96
97	A Randomized, Double-blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma. <i>Oncologist</i> , 2007, 12, 114-123.	1.9	73
98	Liposomal Doxorubicin in Breast Cancer. <i>Women's Health</i> , 2007, 3, 557-569.	0.7	5
99	Carrier-mediated and artificial-cell targeted cancer drug delivery. , 2007, , 469-501.		2
100	Chemotherapeutics and cardiac toxicity: treatment considerations and management strategies. <i>Community Oncology</i> , 2007, 4, 540-548.	0.2	3
101	A phase I/IIa clinical trial of CLAOP21 and CLAOP14 in patients with high grade non-Hodgkins lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1755-1763.	0.6	1
102	Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. <i>Annals of Oncology</i> , 2007, 18, 716-721.	0.6	74
103	Preclinical Rationale, Mechanisms of Action, and Clinical Activity of Anthracyclines in Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S145-S149.	1.4	5
104	Clinical Benefits and Economic Analysis of Pegylated Liposomal Doxorubicin/Vincristine/Dexamethasone Versus Doxorubicin/Vincristine/Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S150-S155.	1.4	18
105	A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2007, 97, 43-49.	2.9	6
106	Feasibility and Cardiac Safety of Pegylated Liposomal Doxorubicin plus Trastuzumab in Heavily Pretreated Patients with Recurrent HER2-Overexpressing Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2007, 7, 690-696.	1.1	29
107	Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: A phase I study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2007, 104, 114-119.	0.6	7
108	Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. <i>Gynecologic Oncology</i> , 2007, 106, 375-380.	0.6	9
109	Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1039-1058.	0.9	271

#	ARTICLE	IF	CITATIONS
110	An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 695-702.	1.1	99
111	Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women $\geq 65$ years of age. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 285-292.	1.1	39
112	Tumor-specific antibody-mediated targeted delivery of Doxil <sup>®</sup> reduces the manifestation of auricular erythema side effect in mice. <i>International Journal of Pharmaceutics</i> , 2008, 357, 272-279.	2.6	62
113	Pegylated Liposomal Doxorubicin. <i>Drugs</i> , 2008, 68, 2535-2551.	4.9	43
114	Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 21-32.	1.4	171
115	Skin penetration from the inside to the outside: A review. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e229-e235.	0.8	11
116	Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents. <i>Oncologist</i> , 2008, 13, 248-260.	1.9	158
117	Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors. <i>Neuroendocrinology</i> , 2008, 88, 53-58.	1.2	68
118	Drug Solubilization with Organic Solvents, or Using Micellar Solutions or Other Colloidal Dispersed Systems. , 2008, , 786-812.		0
119	Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. <i>Anti-Cancer Drugs</i> , 2008, 19, 541-545.	0.7	19
121	Nanomedicine <sup>®</sup> Challenge and Perspectives. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 872-897.	7.2	1,111
122	Pharmacologic Prevention of Anthracycline-Induced Cardiomyopathy. <i>Cardiology in Review</i> , 2009, 17, 243-252.	0.6	11
123	Anticancer therapy induced cardiotoxicity: review of the literature. <i>Anti-Cancer Drugs</i> , 2010, 21, 578-590.	0.7	77
124	Liposomally targeted cytotoxic drugs for the treatment of cancer. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 54, 1573-1600.	1.2	55
125	Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 111-120.	1.1	26
126	Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. <i>Breast</i> , 2010, 19, 33-37.	0.9	25
128	T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. <i>International Journal of Pharmaceutics</i> , 2010, 392, 218-223.	2.6	135
129	Strategies in the design of nanoparticles for therapeutic applications. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 615-627.	21.5	3,124



#	ARTICLE	IF	CITATIONS
130	NANOSCALE SELF-ASSEMBLY FOR DELIVERY OF THERAPEUTICS AND IMAGING AGENTS. Technology and Innovation, 2011, 13, 5-25.	0.2	4
131	Ultrasound-mediated intracellular drug delivery using microbubbles and temperature-sensitive liposomes. Journal of Controlled Release, 2011, 155, 442-448.	4.8	73
132	Quantitative investigation, stability and in vitro release studies of anti-TB drugs in Triton niosomes. Colloids and Surfaces B: Biointerfaces, 2011, 87, 173-179.	2.5	67
133	Pegylated Liposomal Doxorubicin (Caelyx <sup>®</sup> ) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines. Journal of Chemotherapy, 2011, 23, 158-162.	0.7	3
134	A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica, 2011, 96, 245-252.	1.7	62
135	Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Annals of Oncology, 2012, 23, 1780-1788.	0.6	33
136	Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier-Mediated Anticancer Agents. Clinical Pharmacology and Therapeutics, 2012, 91, 802-812.	2.3	61
137	Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine, 2012, 7, 1253-1271.	1.7	491
138	Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 47-69.	1.5	172
139	Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs. Journal of Liposome Research, 2012, 22, 177-192.	1.5	65
140	PolyMPC <sup>®</sup> Doxorubicin Prodrugs. Bioconjugate Chemistry, 2012, 23, 1753-1763.	1.8	89
141	Carrier-Mediated and Targeted Cancer Drug Delivery. , 2012, , 427-452.		0
142	An expert opinion on pharmacologic approaches to reducing the cardiotoxicity of childhood acute lymphoblastic leukemia therapies. Expert Opinion on Pharmacotherapy, 2013, 14, 1497-1513.	0.9	24
143	Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 2013, 65, 36-48.	6.6	3,565
144	Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary?. Gynecologic Oncology, 2013, 129, 544-547.	0.6	29
145	Application of liposomal technologies for delivery of platinum analogs in oncology. International Journal of Nanomedicine, 2013, 8, 3309.	3.3	67
147	Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine, 2014, 9, 1807-1820.	1.7	7
148	Cardiomyopathy Associated With Cancer Therapy. Journal of Cardiac Failure, 2014, 20, 841-852.	0.7	17

#	ARTICLE	IF	CITATIONS
149	Extracellular vesicles as drug delivery systems: Lessons from the liposome field. <i>Journal of Controlled Release</i> , 2014, 195, 72-85.	4.8	372
150	Mussel-inspired protein-mediated surface functionalization of electrospun nanofibers for pH-responsive drug delivery. <i>Acta Biomaterialia</i> , 2014, 10, 1324-1332.	4.1	103
151	Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 95, 13-17.	2.0	37
152	Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1419-1433.	1.5	14
153	Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 597-606.	1.1	38
154	Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index. <i>Anti-Cancer Drugs</i> , 2015, 26, 241-258.	0.7	131
155	Heart failure and chemotherapeutic agents. <i>Future Cardiology</i> , 2015, 11, 453-470.	0.5	5
156	Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1033-1039.	1.1	7
157	Pretherapy Cardiology Evaluation. , 2016, , 345-378.		1
158	Targeted Nanotherapies for the Treatment of Surgical Diseases. <i>Annals of Surgery</i> , 2016, 263, 900-907.	2.1	14
159	Doxorubicin loaded gold nanoparticles: Implication of passive targeting on anticancer efficacy. <i>Pharmacological Research</i> , 2016, 113, 547-556.	3.1	36
160	Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acidâ€“octadecylamine conjugate. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 177-183.	1.9	32
161	Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 123-129.	0.8	5
162	Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells. <i>Saudi Pharmaceutical Journal</i> , 2016, 24, 165-175.	1.2	55
163	To heat or not to heat: Challenges with clinical translation of thermosensitive liposomes. <i>Journal of Controlled Release</i> , 2017, 249, 63-73.	4.8	143
164	A brief review of the management of platinum-resistantâ€“platinum-refractory ovarian cancer. <i>Medical Oncology</i> , 2017, 34, 103.	1.2	125
165	Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600â€“mg/m <sup>2</sup> in recurrent ovarian cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 815-817.	0.7	9
166	Rational designing of an antidote nanoparticle decorated with abiotic polymer ligands for capturing and neutralizing target toxins. <i>Journal of Controlled Release</i> , 2017, 268, 335-342.	4.8	15

#	ARTICLE	IF	CITATIONS
167	Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 787-798.	1.1	28
168	Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity. <i>Oncotarget</i> , 2017, 8, 8383-8396.	0.8	40
169	The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 433.	0.6	1
170	Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension. <i>Frontiers in Physiology</i> , 2018, 9, 890.	1.3	23
171	Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System. <i>Molecular Pharmaceutics</i> , 2019, 16, 3770-3779.	2.3	29
172	Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review. <i>BMC Infectious Diseases</i> , 2019, 19, 848.	1.3	3
173	Mathematical and computational modeling of nano-engineered drug delivery systems. <i>Journal of Controlled Release</i> , 2019, 307, 150-165.	4.8	56
174	Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring. <i>Molecular Pharmacology</i> , 2019, 96, 219-232.	1.0	211
175	Advanced drug delivery system with nanomaterials for personalised medicine to treat breast cancer. <i>Journal of Drug Delivery Science and Technology</i> , 2019, 52, 1051-1060.	1.4	37
176	Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 153-157.	1.2	1
177	A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer. <i>Oncology Research and Treatment</i> , 2019, 42, 269-274.	0.8	6
178	Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 2019, 25, e144118.	0.8	33
179	Graphene-modified electrodes for sensing doxorubicin hydrochloride in human plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 1509-1516.	1.9	39
180	Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 289-291.	0.8	0
181	Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1274-1281.	0.6	5
182	Application of Nanotechnology in Cancer Diagnosis and Therapy - A Mini-Review. <i>International Journal of Medical Sciences</i> , 2020, 17, 2964-2973.	1.1	161
183	Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. <i>Seminars in Cancer Biology</i> , 2021, 69, 349-364.	4.3	86
184	Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. <i>Advanced Therapeutics</i> , 2021, 4, 2000203.	1.6	16

#	ARTICLE	IF	CITATIONS
185	Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin. <i>Journal of Liposome Research</i> , 2021, 31, 1-10.	1.5	18
186	The International Endomyocardial Biopsy Position Paper: A Basis for Integration Into Modern Clinical Practice. <i>Journal of Cardiac Failure</i> , 2022, 28, e5-e7.	0.7	4
187	Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. <i>Frontiers in Oncology</i> , 2021, 11, 645026.	1.3	4
188	Cardiovascular Effects of Cancer Therapy. <i>Pediatric Oncology</i> , 2015, , 167-199.	0.5	1
189	Acute lymphoblastic leukemia in the elderly. <i>The Hematology Journal</i> , 2002, 3, 219-223.	2.0	27
190	Cytotoxic Therapy and Other Nonhormonal Approaches for the Treatment of Metastatic Breast Cancer. , 2002, , 417-472.		1
191	Surviving Cancer without a Broken Heart. <i>Rambam Maimonides Medical Journal</i> , 2019, 10, e0012.	0.4	5
192	Cytotoxic Therapy and Other Nonhormonal Approaches for the Treatment of Metastatic Breast Cancer. , 2002, , 439-494.		0
193	Anthracyclines and Bortezomib. , 2004, , 171-180.		0
194	Case Study: DOXIL, the Development of Pegylated Liposomal Doxorubicin. , 2005, , 459-512.		0
196	Gynecologic Cancer. , 2013, , 163-246.		0
197	Niosomes. , 2013, , 65-90.		1
199	Less Toxic Chemotherapy in Locally Advanced Breast Cancer. <i>Southern Medical Journal</i> , 2020, 113, 559-563.	0.3	1
200	Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. <i>International Journal of Nanomedicine</i> , 2007, 2, 567-83.	3.3	137
201	Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma. <i>Biologics: Targets and Therapy</i> , 2009, 3, 385-90.	3.0	13
202	Replacement of conventional doxorubicin by pegylated liposomal doxorubicin in standard RCHOP chemotherapy for elderly diffuse large B-Cell lymphoma: a retrospective study in China. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 22497-502.	1.3	10
203	Rare, disseminated Kaposi sarcoma in advanced HIV with high-burden pulmonary and skeletal involvement. <i>BMJ Case Reports</i> , 2021, 14, e245448.	0.2	1
204	Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. <i>Journal of Clinical Oncology</i> , 2022, 40, 294-306.	0.8	17

#	ARTICLE	IF	CITATIONS
205	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics. Chinese Chemical Letters, 2022, , .	4.8	3
206	Exploring the impact of physicochemical properties of liposomal formulations on their in vivo fate. Life Sciences, 2022, 300, 120574.	2.0	23
207	Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma. Biologics: Targets and Therapy, 2009, 3, 385.	3.0	7
208	Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. Journal of Ovarian Research, 2022, 15, .	1.3	11
210	A Review on Nanotechnology in Cancer Diagnosis and Therapy: it's Application. , 2022, 8, 1-7.		0
211	Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study. Breast Cancer Research and Treatment, 2023, 199, 67-79.	1.1	2
212	Efficacy of regional cooling+oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin. Supportive Care in Cancer, 2023, 31, .	1.0	1